Aquestive Therapeutics Inc Cash Flow Conversion Efficiency
Aquestive Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has a cash flow conversion efficiency ratio of 0.435x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.81 Million) by net assets ($-34.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aquestive Therapeutics Inc (2005–2025)
Cash flow conversion efficiency of Aquestive Therapeutics Inc from 2005 to 2025. This chart illustrates how Aquestive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Aquestive Therapeutics Inc for real-time trading data and today's change.
Aquestive Therapeutics Inc Cash Flow Conversion Ratio Explained
Aquestive Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aquestive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aquestive Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Aquestive Therapeutics Inc (AQST) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
0.034x |
|
Changchun Gas Co Ltd
SHG:600333
|
-0.006x |
|
Zhangjiagang Guangda Special Material Co Ltd
SHG:688186
|
-0.017x |
|
Lake Materials Co. Ltd.
KQ:281740
|
0.006x |
|
Grupo Supervielle S.A
F:189A
|
0.176x |
|
China Oil HBP Science & Technology Co Ltd
SHE:002554
|
-0.120x |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
0.058x |
|
Northern United Publishing & Media Group Co Ltd
SHG:601999
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Aquestive Therapeutics Inc from 2005 to 2025. Review AQST cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.66 Million | $-52.43 Million | 1.558x | +162.03% |
| 2024-12-31 | $-60.16 Million | $-35.76 Million | 0.594x | +892.16% |
| 2023-12-31 | $-106.49 Million | $-6.38 Million | 0.060x | -27.44% |
| 2022-12-31 | $-118.55 Million | $-9.79 Million | 0.083x | -79.44% |
| 2021-12-31 | $-82.13 Million | $-32.98 Million | 0.402x | -57.16% |
| 2020-12-31 | $-48.50 Million | $-45.46 Million | 0.937x | -90.47% |
| 2019-12-31 | $-6.12 Million | $-60.21 Million | 9.835x | +863.12% |
| 2018-12-31 | $10.08 Million | $-12.99 Million | -1.289x | -486.31% |
| 2017-12-31 | $-26.50 Million | $5.82 Million | -0.220x | -147.26% |
| 2016-12-31 | $-17.58 Million | $-8.18 Million | 0.465x | +226.96% |
| 2006-12-31 | $25.26 Million | $-9.26 Million | -0.366x | +73.28% |
| 2005-12-31 | $4.67 Million | $-6.39 Million | -1.371x | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more